RxDoctor Payments Data

John Lacy, MD

Internal Medicine · Greenville, SCNPI 1992964159

Payments from drug & device makers

$827in general payments, 2019–2025

Across 49 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$138
  • Dexcom, Inc.$114
  • Amgen$90
  • Pfizer$72
  • Inari Medical, Inc.$69
  • Novartis$53
  • plus $291 from 11 others

What the payments were for

  • Food & beverage$827100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$827 in reported general payments places this provider in the 65th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$189,761
Medicare patients
371
Services billed
2,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin150$173,418
RybelsusSemaglutide65$112,499
OzempicSemaglutide77$109,141
JanuviaSitagliptin Phosphate42$53,127
FarxigaDapagliflozin Propanediol25$27,955
Tresiba Flextouch U-100Insulin Degludec50$27,889
MounjaroTirzepatide18$27,040
TrulicityDulaglutide20$27,029
EliquisApixaban21$23,639
Tresiba Flextouch U-200Insulin Degludec35$20,658
InvokanaCanagliflozin11$18,614
XareltoRivaroxaban22$18,309
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$17,990
MyrbetriqMirabegron13$17,079
Rosuvastatin Calcium975$14,888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$138$221,640142 claims
Boehringer IngelheimJardiance$11$173,418150 claims
MerckJanuvia$14$53,12742 claims
GSKAnoro Ellipta, Breo Ellipta$44$28,47058 claims
PfizerEliquis$72$23,63921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →